| Name | Title | Contact Details |
|---|
Founded by Dr. Samuel Brown, Brown Fertility is a fully comprehensive fertility clinic offering patients exceptional results through personalized care and affordable treatment plans. With over 15 years experience and the management of more than 5,000 IVF cycles, Dr. Samuel Brown consistently achieves success rates above the national average. From basic evaluation and testing to the most advanced procedures and treatments available, Brown Fertility is dedicated to Conceiving Miracles™.
Preferred Health Systems is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gravie has been at the forefront of driving change and improving the healthcare industry by creating innovative employer-sponsored health benefit solutions that put consumers first. Comfort™, Gravie`s flagship product, is the nation`s first-of-its-kind health plan that provides zero-deductible, zero-copay, and 100% coverage on most common healthcare services, at a cost comparable to most traditional group health plans.
Laurels Of Norworth is a Worthington, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.